Nobel Laureate Aghion: Competition-Friendly Subsidies Spur Innovation

The recent recognition of Philippe Aghion as a Nobel laureate in economics on October 13th brings renewed attention to his groundbreaking work on industrial policy. A timely article co-authored by Aghion, Mathias Dewatripont, and Patrick Legros, previously published in the CPI Antitrust Chronicle, advocates for a paradigm shift: "competition-friendly" industrial policy. This perspective offers crucial insights for leaders across banking, payments, and FinTech sectors who are currently navigating a landscape where governments are channeling substantial investments into critical areas such as semiconductors, clean technologies, and health innovation.

Aghion and his co-authors challenge the conventional understanding of industrial policy, asserting that it need not devolve into the pitfalls of selecting national champions or safeguarding underperforming entities. Instead, they propose a strategic framework where industrial policy is meticulously designed to operate in synergy with competition policy. Under this approach, targeted, sector-specific governmental support can significantly accelerate innovation and enhance overall productivity. Their argument is bolstered by a blend of theoretical models and empirical evidence, notably drawing lessons from China's economic trajectory. Furthermore, they highlight the U.S. Advanced Research Project Agencies (ARPAs) as an exemplary template, demonstrating how focused public funding can foster intense competition among multiple teams, underpinned by clear milestones and robust accountability mechanisms.

The Synergy of Competition and Industrial Policy

One of the core tenets of Aghion's research is the complementary relationship between competition and industrial policy. Far from being opposing forces, they can be powerful allies in driving economic progress. The authors' model elucidates that firms are more inclined to invest in truly breakthrough ideas when confronted by genuine rivals, rather than operating within comfortable monopolies. Consequently, effective policy should strategically channel activity towards markets where innovation yields the most substantial returns. Crucially, support should be widely distributed across numerous firms, rather than concentrated within a singular "national champion." This dispersion of aid, coupled with stringent antitrust safeguards designed to prevent collusion, cultivates a more dynamic environment, leading to accelerated innovation and faster diffusion of new technologies.

Design Details Matter: Lessons from China

The efficacy of industrial policy hinges significantly on its design nuances, a fact demonstrably proven by China's extensive experience. Through an in-depth study of Chinese firms between 1998 and 2007, the authors identified that certain policy instruments, such as direct subsidies and tax holidays, correlated positively with higher total factor productivity. Conversely, other interventions, including inexpensive loans and tariffs, did not yield similar benefits. The research further indicates that positive outcomes are magnified when support is dispersed across various entities and when smaller firms are made eligible for assistance. A critical observation from China's case, however, was a missed opportunity: authorities often failed to direct more aid towards the most competitive markets, thereby leaving potential gains unrealized.

The ARPA Playbook: A Competitive Approach to "Picking Winners"

The ARPA model provides a compelling blueprint for how to "pick winners" through competitive mechanisms. A prime example is the Biomedical Advanced Research and Development Authority (BARDA)'s COVID-19 program. This initiative strategically allocated substantial, milestone-based funding to six distinct vaccine teams, encompassing three diverse technologies—mRNA, viral vector, and protein subunit—while encouraging global participation. This involved multi-billion-dollar investments, such as approximately $2.48 billion for Moderna and about $1.95 billion for BioNTech/Pfizer. Remarkably, all six projects ultimately secured authorization in either the U.S. or the European Union. This demonstrates a sophisticated form of industrial policy that effectively sustains market rivalry while simultaneously addressing critical coordination bottlenecks, leading to rapid and successful innovation in areas of national interest.

Further Insights and Policy Implications

Beyond these core findings, the paper sheds light on several other pertinent areas. It highlights European innovations in procurement, such as joint EU vaccine purchases, which not only improved access but also created significant buyer leverage. This approach, the authors suggest, could be replicated to mitigate the high costs associated with rare-disease drugs by curbing "divide-and-conquer" pricing strategies across different countries.

Furthermore, the research points to critical governance improvements. The proliferation of "me too" products, which offer only marginal improvements, can be curtailed by elevating approval standards. This ensures that both public funding and private research and development efforts are channeled towards genuine breakthroughs rather than incremental adjustments. From a political economy perspective, channeling aid towards more competitive and less concentrated sectors can effectively diminish rent-seeking pressures and mitigate lobbying distortions, fostering a healthier, more equitable innovation ecosystem.

The overarching takeaway for Europe is particularly salient: while existing programs like the European Innovation Council serve valuable purposes, the region currently lacks a true DARPA/BARDA-style engine. Such an engine is crucial for catalyzing disruptive investments in strategic sectors and could be instrumental in addressing Europe's noted productivity slump relative to the U.S. The insights provided by Aghion, Dewatripont, and Legros offer a comprehensive framework for designing industrial policies that are not only effective but also inherently competition-friendly, promising a future of accelerated innovation and enhanced economic vitality.